SAN DIEGO--(BUSINESS WIRE)--Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed ...

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, ...

Daniel Bradbury's most active month to dispose stocks was the month of July. 2012 saw Daniel Bradbury paying a total of $7,130,250.15 for 902,922 shares, this is the most they've acquired in one year.

, a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, announced today that Daniel M. Bradbury ...

Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Corcept Therapeutics announced that Daniel M. Bradbury has been appointed to the company's Board of Directors.

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical ...